Literature DB >> 18166520

Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.

Kishore P V1, Subish Palaian, Pradip Ojha, Shankar P R.   

Abstract

Tuberculosis is a common problem in developing countries including Nepal. Data regarding the safety profile of anti tubercular drugs is lacking in Nepal. The present study analyzed the pattern of ADRs caused by the antitubercular drugs. Inpatient files of all the TB patients who received treatment at the Manipal Teaching Hospital, Pokhara, Nepal during the period from 1st January 2001 till 31st December 2006 were taken. Altogether 326 patients were identified among which 40 (females 24, males 16) experienced at least one ADR (incidence 12.27%). The mean+/-SD age of the patients was 42.12+/-20.41 years. The most common ADR was elevated liver enzymes [24 (57.14%)] and hepatobiliary system was the most common system affected [24 (58.5%)]. More than half the ADRs [21 (52.55%)] developed with in 20 days of initiation of therapy. Isoniazid and pyrazinamide were the suspected drugs responsible for 32.32% each of the total ADRs. The mean+/-SD of the total number of drugs used in the patients were 4.77+/-1.46. The most common laboratory abnormality observed was elevated SGOT level [21 patients (52.5%)]. Seven (17.5%) patients needed specific drug treatment for managing the ADRs and 10 (25%) needed symptomatic management. Thirty five (87.5%) patients recovered following the ADR. Multiple drug therapy was the reason behind the development of 30 (75%) ADRs. It was found that 29 (72.5%) ADRs were 'probably' due to the suspected drugs. Majority [19 (47.5%)] of the ADRs were mild [level (1)]. This study shows that ADRs to anti tubercular drugs are common. Since TB is a common problem in Nepal, special efforts are needed to tackle the drug related complications associated with ATT drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18166520

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  10 in total

1.  Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy.

Authors:  Shamiya Sadiq; Vijay Khajuria; Vishal R Tandon; Annil Mahajan; Jang B Singh
Journal:  J Clin Diagn Res       Date:  2015-10-01

2.  Biomarkers of oxidative stress and personalized treatment of pulmonary tuberculosis: emerging role of gamma-glutamyltransferase.

Authors:  Etienne Mokondjimobe; Benjamin Longo-Mbenza; Jean Akiana; Ulrich Oswald Ndalla; Regis Dossou-Yovo; Joseph Mboussa; Henri-Joseph Parra
Journal:  Adv Pharmacol Sci       Date:  2012-05-07

3.  National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program.

Authors:  Driss Soussi Tanani; Samira Serragui; Sanae Hammi; Latifa Ait Moussa; Abdelmajid Soulaymani; Rachida Soulaymani; Yahia Cherrah
Journal:  Pan Afr Med J       Date:  2017-01-31

4.  Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal.

Authors:  Sunil Shrestha; Krisha Danekhu; Bhuvan Kc; Subish Palaian; Mohamed Izham Mohamed Ibrahim
Journal:  Ther Adv Drug Saf       Date:  2020-06-12

5.  Evaluation of Adverse Reactions Induced by Anti-Tuberculosis Drugs in Hospital Pulau Pinang.

Authors:  Cheah Meng Fei; Hadzliana Zainal; Irfhan Ali Hyder Ali
Journal:  Malays J Med Sci       Date:  2018-10-30

6.  Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).

Authors:  Yin Yin Xia; Dai Yu Hu; Fei Ying Liu; Xiao Meng Wang; Yan Li Yuan; De Hua Tu; Yi Xin Chen; Lin Zhou; Li Zhen Zhu; Wei Wei Gao; Hong Yuan Wang; Da Fang Chen; Li Yang; Ping Ping He; Xiao Ting Li; Ying Jian He; Feng Sun; Si Yan Zhan
Journal:  BMC Public Health       Date:  2010-05-21       Impact factor: 3.295

7.  Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil.

Authors:  Glauciene Santana Damasceno; Lusiele Guaraldo; Elyne Montenegro Engstrom; Mariza Miranda Theme Filha; Reinaldo Souza-Santos; Ana Gloria Godoi Vasconcelos; Suely Rozenfeld
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

8.  Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.

Authors:  Evans Sagwa; Nunurai Ruswa; Jean Paul Musasa; Aukje K Mantel-Teeuwisse
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.228

9.  Pharmacovigilance and moroccan tuberculosis public program: current situation.

Authors:  Driss Soussi Tanani; Amina Tebaa; Raja Benkirane; Kenza Bennani; Ghali Iraqi; Abdelmajid Soulaymani; Rachida Soulaymani Bencheikh
Journal:  Tuberc Res Treat       Date:  2014-06-12

10.  Intuitive weights of harm for therapeutic decision making in smear-negative pulmonary Tuberculosis: an interview study of physicians in India, Pakistan and Bangladesh.

Authors:  Chandrashekhar T Sreeramareddy; Mahbubur Rahman; H N Harsha Kumar; Mohsin Shah; Ahmed Manadir Hossain; Md Abu Sayem; Juan M Moreira; Jef Van den Ende
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-08       Impact factor: 2.796

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.